Skip Navigation

Corrigendum for Herrmann et al., Cardiovasc Res 61 (1) 11-21.
Cardiovascular Research 2004 63(4):756; doi:10.1016/j.cardiores.2004.06.015
© 2004 by European Society of Cardiology
This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Correction (v61,p11)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Herrmann, J.
Right arrow Articles by Lerman, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Herrmann, J.
Right arrow Articles by Lerman, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2004, European Society of Cardiology

Corrigendum to: "The ubiquitin–proteasome system in cardiovascular diseases—a hypothesis extended" [Cardiovasc. Res. 61 (2004) 11–21]

Joerg Herrmann*,a, Aaron Ciechanoverb, Lilach O Lermanc and Amir Lermana

aDivision of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA
bRappaport Institute for Research in Medical Sciences, Technion-Israel Institute of Technology, Haifa, Israel
cDivision of Hypertension, Mayo Clinic, Rochester, MN, USA

* Corresponding author. Department of Internal Medicine, Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA. Tel.: +1-507-255-5890; fax: +1-507-255-1824. Email address: herrmann.joerg{at}mayo.edu

As an addendum to our recent review, entitled "The ubiquitin–proteasome system in cardiovascular diseases—a hypothesis extended" [Cardiovasc. Res. 61 (2004) 11–21], it should be noted that boronate-type proteasome inhibitors are eventually reversible in their effect, although boronate-proteasome adducts have a very slow dissociation rate, constituting a mode of inhibition that is practically irreversible over hours. Furthermore, the majority of reports attribute not only reversibility, but also selectivity to boronate-type proteasome inhibitors, and appropriate revisions were made to Table 2 to remain most accurate in these aspects [1]. In addition, it should be mentioned that the enzymatic β1 sites, which were traditionally considered to harbor "peptidyl glutamyl peptide hydrolase" activity, cleave faster after aspartic acid than after glutamate residues, hence favoring the label "caspase-like activity". Also, to be more informative, a grading of the effect of the various inhibitors on the different enzymatic activities of the 20S proteasome was provided in the revised version of Table 2.


View this table:
[in this window]
[in a new window]

  		Table 2 Classes and characteristics of proteasome inhibitors (modified from Kisselev AF, Goldberg AL. Chem Biol 2001;8:738–58)

 


   References
Top
 References
 

  1. Kisselev A.F., Goldberg A.L. Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. (2001) 8:739–758.[CrossRef][Web of Science][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Correction (v61,p11)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Herrmann, J.
Right arrow Articles by Lerman, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Herrmann, J.
Right arrow Articles by Lerman, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?